Sanofi’s Foundation S and Sobi Renew Partnership with WFH Humanitarian Aid Program

Sanofi’s Foundation S and Sobi Renew Partnership with WFH Humanitarian Aid Program

(IN BRIEF) Sanofi and Sobi have renewed their partnership with the World Federation of Hemophilia (WFH) to support the WFH Humanitarian Aid Program for up to five years. The new agreement includes the donation of up to 100 million international units (IU) of factor therapy annually to aid individuals with inherited bleeding disorders in developing countries. This extension celebrates the tenth anniversary of their collaboration, which has already seen one billion IUs donated, benefiting over 22,000 patients. The partners remain committed to advancing treatment access and improving patient outcomes globally.

(PRESS RELEASE) PARIS, 25-Apr-2025 — /EuropaWire/ — Sanofi, through its philanthropic organization Foundation S, and Sobi, in collaboration with the World Federation of Hemophilia (WFH) and WFH USA, have announced the extension of their partnership for up to five years to support the WFH Humanitarian Aid Program. This renewal is the second in a decade-long collaboration and highlights the continued commitment of the partners to providing essential care and resources to individuals living with hemophilia globally.

As part of the extended agreement, Sanofi and Sobi will donate up to 100 million international units (IU) of factor therapy annually, which will be distributed to developing countries through the WFH Humanitarian Aid Program. This donation will help support the treatment of individuals with inherited bleeding disorders in underserved regions worldwide.

This announcement marks the tenth anniversary of the partnership’s initiation, where Sanofi and Sobi responded to the WFH’s call for action to aid the global community of individuals with inherited bleeding disorders. Over the past decade, the collaboration has resulted in the donation of one billion IUs of treatment, reaching over 22,000 individuals with hemophilia.

Alaa Hamed, Global Head of Medical Affairs for Rare Diseases at Sanofi, stated, “This new agreement builds on the legacy of our original ten-year, one billion IU commitment. It reinforces our ongoing dedication to creating a sustainable, predictable program that meets the needs of individuals with hemophilia worldwide. Our efforts have expanded treatment access, transforming patient outcomes, and we are proud to continue leveraging Foundation S to improve the quality of life for thousands of people in developing countries.”

Lydia Abad-Franch, Head of R&D and Chief Medical Officer at Sobi, added, “We are honored to continue supporting the WFH Humanitarian Aid Program. Since the beginning of this partnership, over 22,000 people with hemophilia have received treatment. We look forward to further strengthening our partnership with WFH and making a positive impact on the lives of those affected by bleeding disorders.”

Cesar Garrido, President of the WFH, remarked, “The contributions of Sanofi and Sobi to the Humanitarian Aid Program have been invaluable, especially in the last decade. This new five-year contract ensures the continuation of their support, helping us achieve our shared vision of Treatment for All.”

Mark Skinner, a Board Member of the WFH in the USA, emphasized, “The WFH Humanitarian Aid Program exemplifies what can be accomplished through collaboration. The leadership of Sobi and Sanofi has provided inspiration to others in the industry, hope to patients, and strengthened healthcare professionals’ capacity around the world.”

About the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor.

Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world.

To find out more about the WFH, please visit www.wfh.org.

About WFH USA
WFH USA furthers the mission of the WFH in the U.S. by deepening engagement of American citizens with our global vision of Treatment for All and raising funds to bring that vision to life. By working with the World Federation of Hemophilia, we help transform communities by equipping and empowering WFH national member organizations (NMOs) and healthcare providers with the knowledge and tools they need to identify, support and treat people living with bleeding disorders around the world. To find out more about WFH USA, please visit wfh.org/usa.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Foundation S – The Sanofi Collective
Foundation S strives to create healthier futures for generations to come. We are driven by a singular purpose: to improve the lives of vulnerable populations by catalyzing community–based solutions, expanding access to medicines, and mobilizing collective action.

About Sobi
Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Media Contacts:

WFH Media Relations
Neha Suchak | +1 514 875 7944 #2857 | nsuchak@wfh.org

Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Nicolas Obrist | +33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com

Sobi Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

SOURCE: Sanofi